IRCCS MultiMedica
Published September 28, 2022 | Version v1
Dataset Restricted

Results of a prospective observational study of autologous peripheral blood mononuclear cell therapy for no-option critical limb-threatening ischemia and severe diabetic foot ulcers

Creators

  • 1. Diabetic Foot Dpt, IRCCS MultiMedica, Milan, Italy
  • 2. Value-based Healthcare Unit, IRCCS MultiMedica, Milan, Italy
  • 3. Laboratory of Cardiovascular Pathophysiology-Regenerative Medicine, IRCCS MultiMedica, Milan, Italy
  • 4. Diabetic Foot Dpt, IRCCS MultiMedica, Milan, Italy; Unit of Endocrinology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
  • 5. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • 6. Vascular Surgery Unit, IRCCS MultiMedica, Milan, Italy
  • 7. Interventional Cardiology Unit, IRCCS MultiMedica, Milan, Italy
  • 8. Diabetic Foot Unit, University of Rome Tor Vergata, Rome, Italy
  • 9. CTO Andrea Alesini Hospital, Division of Endocrinology and Diabetes, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
  • 10. Laboratory of Immunology and General Pathology, Department of Biotechnologies and Life Sciences, University of Insubria, Varese, Italy; Laboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry and Immunology, IRCCS MultiMedica, Milan, Italy
  • 11. Laboratory of Cardiovascular Pathophysiology-Regenerative Medicine, IRCCS MultiMedica, Milan, Italy.

Description

Abstract
Background: Cell therapy with autologous peripheral blood mononuclear cells (PB-MNCs) may help restore limb
perfusion in patients with diabetes mellitus and critical limb-threatening ischemia (CLTI) deemed not eligible for
revascularization procedures and consequently at risk for major amputation (no-option). Fundamental is to establish
its clinical value and to identify candidates with a greater benefit over time. Assessing the frequency of PB circulating
angiogenic cells and extracellular vesicles (EVs) may help in guiding candidate selection.
Methods: We conducted a prospective, non-controlled, observational study on no-option CLTI diabetic patients that
underwent intramuscular PB-MNCs therapy, which consisted of more cell treatments repeated a maximum of three
times. The primary endpoint was amputation rate at 1 year following the first treatment with PB-MNCs. We evaluated
ulcer healing, walking capability, and mortality during the follow-up period. We assessed angiogenic cells and EVs
at baseline and after each cell treatment, according to primary outcome and tissue perfusion at the last treatment
[measured as transcutaneous oxygen pressure (
TcPO2)].
Results: 50 patients were consecutively enrolled and the primary endpoint was 16%. TcPO2
increased after PB-MNCs
therapy (17.2 ± 11.6 vs 39.1 ± 21.8 mmHg, p < .0001), and ulcers healed with back-to-walk were observed in 60%
of the study population (88% of survivors) during follow-up (median 1.5 years). Patients with a high level of TcPO2
(≥ 40 mmHg) after the last treatment showed a high frequency of small EVs at enrollment.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:

Data are accessible upon request to the corresponding author, Gaia Spinetti.

You are currently not logged in. Do you have an account? Log in here